Laura Pacini

Laura Pacini

Auto-generated profile, based on publicly available information

Laura Pacini

University of Rome ‘Tor Vergata

Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 December 2003 in Journal of Virology
Verified
Journal Article
Open access
PDF file
LTLicia Tomei
Licia Tomei
SASergio Altamura
Sergio Altamura
LBLinda Bartholomew
Linda Bartholomew
ABAntonino Biroccio
Antonino Biroccio
ACAlessandra Ceccacci
Alessandra Ceccacci
GMGiovanni Migliaccio
Giovanni Migliaccio
The RNA-dependent RNA polymerase of hepatitis C virus (HCV) is the catalytic subunit of the viral RNA amplification machinery and is an appealing target for the development of new therapeutic agents against HCV infection. Nonnucleoside inhibitors based on a benzimidazole scaffold have been recently reported. Compounds of this class are efficient inhibitors of HCV RNA replication in cell culture, thus providing attractive candidates for further development. Here we report the detailed analysis of the mechanism of action of selected benzimidazole inhibitors. Kinetic data and binding experiments indicated that these compounds act as allosteric inhibitors that block the activity of the polymerase prior to the elongation step. Escape mutations that confer resistance to these compounds map to proline 495, a residue located on the surface of the polymerase thumb domain and away from the active site. Substitution of this residue is sufficient to make the HCV enzyme and replicons resistant to the inhibitors. Interestingly, proline 495 lies in a recently identified noncatalytic GTP-binding site, thus validating it as a potential allosteric site that can be targeted by small-molecule inhibitors of HCV polymerase.

13 November 2013 in Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
AJAleksandra Janusz
Aleksandra Janusz
JMJacek Miłek
Jacek Miłek
MPMałgorzata Perycz
Małgorzata Perycz
LPLaura Pacini
Laura Pacini
CBClaudia Bagni
Claudia Bagni
MDMagdalena Dziembowska
Magdalena Dziembowska
Activity-dependent protein synthesis at synapses is dysregulated in the Fragile X syndrome (FXS). This process contributes to dendritic spine dysmorphogenesis and synaptic dysfunction in FXS. Matrix Metalloproteinase 9 (MMP-9) is an enzyme involved in activity-dependent reorganization of dendritic spine architecture and was shown to regulate spine morphology in a mouse model of FXS, the Fmr1 knock-out mice. Here we show that MMP-9 mRNA is part of the FMRP complex and colocalizes in dendrites. In the absence of FMRP MMP-9 mRNA translation is increased at synapses, suggesting that this mechanism contributes to the increased metalloproteinase level at synapses of Fmr1 knock-out mice. We propose that such a local effect can contribute to the aberrant dendritic spine morphology observed in the Fmr1 knock-out mice and in patients with FXS.

15 March 2003 in Journal of Virology
Verified
Journal Article
Closed access
PDF file
CTCaterina Trozzi
Caterina Trozzi
LBLinda Bartholomew
Linda Bartholomew
ACAlessandra Ceccacci
Alessandra Ceccacci
GBGabriella Biasiol
Gabriella Biasiol
LPLaura Pacini
Laura Pacini
GMGiovanni Migliaccio
Giovanni Migliaccio
The hepatitis C virus (HCV) serine protease is necessary for viral replication and represents a valid target for developing new therapies for HCV infection. Potent and selective inhibitors of this enzyme have been identified and shown to inhibit HCV replication in tissue culture. The optimization of these inhibitors for clinical development would greatly benefit from in vitro systems for the identification and the study of resistant variants. We report the use HCV subgenomic replicons to isolate and characterize mutants resistant to a protease inhibitor. Taking advantage of the replicons9 ability to transduce resistance to neomycin, we selected replicons with decreased sensitivity to the inhibitor by culturing the host cells in the presence of the inhibitor and neomycin. The selected replicons replicated to the same extent as those in parental cells. Sequence analysis followed by transfection of replicons containing isolated mutations revealed that resistance was mediated by amino acid substitutions in the protease. These results were confirmed by in vitro experiments with mutant enzymes and by modeling the inhibitor in the three-dimensional structure of the protease.

1 October 2015 in Neurobiology of Learning and Memory
Verified
Journal Article
Closed access
EPE. Pasciuto
E. Pasciuto
SBS.C. Borrie
S.C. Borrie
AKAlexandros Kanellopoulos
Alexandros Kanellopoulos
ASA.R. Santos
A.R. Santos
ECE. Cappuyns
E. Cappuyns
CBClaudia Bagni
Claudia Bagni

1 July 2015 in Neuron
Verified
Journal Article
Closed access
EPEmanuela Pasciuto
Emanuela Pasciuto
TATariq Ahmed
Tariq Ahmed
TWTina Wahle
Tina Wahle
FGFabrizio Gardoni
Fabrizio Gardoni
LDLaura D’aNdrea
Laura D’aNdrea
CBClaudia Bagni
Claudia Bagni

5 September 2017 in RNA Biology
Verified
Journal Article
Open access
AFAlice Filippini
Alice Filippini
DBDaniela Bonini
Daniela Bonini
CLCaroline Lacoux
Caroline Lacoux
LPLaura Pacini
Laura Pacini
MZMaria Zingariello
Maria Zingariello
Alessandro BarbonAlessandro Barbon
Alessandro Barbon
The fragile X syndrome (FXS), the most common form of inherited intellectual disability, is due to the absence of FMRP, a protein regulating RNA metabolism. Recently, an unexpected function of FMRP in modulating the activity of Adenosine Deaminase Acting on RNA (ADAR) enzymes has been reported both in Drosophila and Zebrafish. ADARs are RNA-binding proteins that increase transcriptional complexity through a post-transcriptional mechanism called RNA editing. To evaluate the ADAR2-FMRP interaction in mammals we analyzed several RNA editing re-coding sites in the fmr1 knockout (KO) mice. Ex vivo and in vitro analysis revealed that absence of FMRP leads to an increase in the editing levels of brain specific mRNAs, indicating that FMRP might act as an inhibitor of editing activity. Proximity Ligation Assay (PLA) in mouse primary cortical neurons and in non-neuronal cells revealed that ADAR2 and FMRP co-localize in the nucleus. The ADAR2-FMRP co-localization was further observed by double-immunogold Electron Microscopy (EM) in the hippocampus. Moreover, ADAR2-FMRP interaction appeared to be RNA independent. Because changes in the editing pattern are associated with neuropsychiatric and neurodevelopmental disorders, we propose that the increased editing observed in the fmr1-KO mice might contribute to the FXS molecular phenotypes.